Recombinant Human Delta-like protein 4 (DLL4), partial (Active)

^{In
Stock}

品名簡稱：

Recombinant Human DLL4 protein, partial (Active)
貨號：

CSB-MP878862HU
說明書：

MSDS Datasheet
規格：

￥588
圖片：
(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.

Activity
Measured by its binding ability in a functional ELISA. Immobilized Human DLL4 at 2 μg/ml can bind Anti-DLL4 recombinant antibody (CSB-RA878862MA1HU). The EC₅₀ is 2.322-2.607 ng/mL. Biological Activity Assay
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

純度：

Greater than 95% as determined by SDS-PAGE.
內毒素：

Less than 1.0 EU/ug as determined by LAL method.
生物活性：

Measured by its binding ability in a functional ELISA. Immobilized Human DLL4 at 2 μg/mL can bind Anti-DLL4 recombinant antibody (CSB-RA878862MA1HU). The EC50 is 2.322-2.607 ng/mL.
基因名：

DLL4
Uniprot No.：

Q9NR61
別名：

Delta-like protein 4; Drosophila Delta homolog 4?(Delta4); DLL4; UNQ1895/PRO4341
種屬：

Homo sapiens (Human)
蛋白長度：

Partial
來源：

Mammalian cell
分子量：

55.7 kDa
表達區域：

27-524aa
氨基酸序列

SGVFQLQLQEFINERGVLASGRPCEPGCRTFFRVCLKHFQAVVSPGPCTFGTVSTPVLGTNSFAVRDDSSGGGRNPLQLPFNFTWPGTFSLIIEAWHAPGDDLRPEALPPDALISKIAIQGSLAVGQNWLLDEQTSTLTRLRYSYRVICSDNYYGDNCSRLCKKRNDHFGHYVCQPDGNLSCLPGWTGEYCQQPICLSGCHEQNGYCSKPAECLCRPGWQGRLCNECIPHNGCRHGTCSTPWQCTCDEGWGGLFCDQDLNYCTHHSPCKNGATCSNSGQRSYTCTCRPGYTGVDCELELSECDSNPCRNGGSCKDQEDGYHCLCPPGYYGLHCEHSTLSCADSPCFNGGSCRERNQGANYACECPPNFTGSNCEKKVDRCTSNPCANGGQCLNRGPSRMCRCRPGFTGTYCELHVSDCARNPCAHGGTCHDLENGLMCTCPAGFSGRRCEVRTSIDACASSPCFNRATCYTDLSTDTFVCNCPYGFVGSRCEFPVGLP
蛋白標簽：

C-terminal 10xHis-tagged
產品提供形式：

Lyophilized powder Warning: in_array() expects parameter 2 to be array, null given in /www/web/cusabio_cn/public_html/caches/caches_template/default/content/show_product_protein.php on line 668
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
緩沖液：

Lyophilized from a 0.2 μm filtered PBS, 6% Trehalose, pH 7.4
復溶：

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
儲存條件：

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
保質期：

The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
貨期：

3-7 business days
注意事項：

Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA：

Please contact us to get it.

產品評價

靶點詳情

功能：

Involved in the Notch signaling pathway as Notch ligand. Activates NOTCH1 and NOTCH4. Involved in angiogenesis; negatively regulates endothelial cell proliferation and migration and angiogenic sprouting. Essential for retinal progenitor proliferation. Required for suppressing rod fates in late retinal progenitors as well as for proper generation of other retinal cell types. During spinal cord neurogenesis, inhibits V2a interneuron fate.
基因功能參考文獻：
1. These data indicate that DLL4 represents a new prognostic biomarker for nonsmall cell lung cancer , and DLL4 overexpression inhibits cell proliferation and metastasis in vitro. PMID: 30226615
2. Study demonstrates that DLL4 is important in regulating the tumour growth of hepatitis B virus (HBV)-associated hepatocellular carcinoma as well as the neovascularization and suppression of HBV replication. PMID: 30228780
3. this study revealed that DLL4 has pathophysiological roles on the progression of esophagus cancer cells, including migration, invasion and apoptosis, which indicated that DLL4 may be considered as a potent therapeutic target for the treatment of malignant esophageal cancer. PMID: 29749499
4. The regulation of DLL4 by the LDB2 complex provides a novel mechanism of DLL4 transcriptional control that may be exploited to develop therapeutics for aberrant vascular remodeling. PMID: 28946938
5. Data show that Delta-like 4 (DLL4) and Jagged1 (JAG1) displayed equal potency in stimulating Notch target genes in HMEC-1 dermal microvascular endothelial cells but had opposing effects on sprouting angiogenesis in vitro. PMID: 28445154
6. epigenetic silencing and TP53 mutation have an effect on the expression of DLL4 in human cancer stem disorder PMID: 27542210
7. the Notch signaling and atherosclerosis relevant markers in lesions from femoral arteries of symptomatic peripheral artery disease patients, were characterized. PMID: 28472949
8. Data suggest that Numb acts as a Notch antagonist by controlling intracellular destination and stability of the Notch ligand Delta-like 4 (DLL4) through a post-endocytic sorting process; Numb negatively controls DLL4 plasma membrane recycling through well-documented recycling regulator protein AP1. PMID: 29042443
9. Results show that DLL4 is involved in SYNJ2BP-induced hepatocellular carcinoma (HCC) development though activating its pathway. PMID: 27440153
10. Positive Jagged1 and DLL4 expression is closely correlated with severe clinicopathological characteristics and poor prognosis in patients with gallbladder cancers. PMID: 27174628
11. We show that GIT1, which also contains an ANK domain, inhibits the Notch1-Dll4 signaling pathway by competing with Notch1 ANK domain for binding to RBP-J in stalk cells PMID: 27926858
12. Results provide evidence that DLL4 is associated with gastric cancer stem/progenitor cells (GCSPCs), and its expression impacts CSPC stemness characteristics associated with the Notch-1 pathway including self-renewal, differentiation, proliferation, and tumor formation. PMID: 27891816
13. The authors present novel structures of human ligands Jagged2 and Delta-like4 and human Notch2, together with functional assays, which suggest that ligand-mediated coupling of membrane recognition and Notch binding is likely to be critical in establishing the optimal context for Notch signalling. PMID: 28572448
14. Overexpression of DLL4 could significantly attenuate the cytotoxic effects of docetaxel in MCF-7 cells by increasing Bcl-2 expression, while decreasing Bax expression, apoptosis rate and DNA damage PMID: 27334972
15. In gastric epithelial cells co-cultured with Helicobacter pylori, the expression level of the ligand DLL4 was found to be significantly increased. PMID: 27073072
16. Low DLL4 abundance in tumour cells may predict the benefit from adjuvant gemcitabine therapy after PDAC resection. PMID: 27755532
17. Angiogenesis in Infantile haemangioma (IH) appears to be controlled by DLL4 within the endothelium in a VEGF-A isoform-dependent manner, and in perivascular cells in a VEGF-independent manner. The contribution of VEGF-A isoforms to disease progression also indicates that IH may be associated with altered splicing. PMID: 26957058
18. Dll4 modulates liver inflammatory response by down-regulating chemokine expression PMID: 27171900
19. Positive Jagged1 and DLL4 expression is closely correlated with severe clinicopathological characteristics and poor prognosis in patients with pancreatic ductal carcinoma. PMID: 27919854
20. Data show that the IgA/delta-like protein 4 (Delta-4)/Notch receptor (Notch) axis is not observed in IgG-dendritic cells (DCs). PMID: 27117596
21. Data suggest that the vascular DLL4-Notch4 signaling and VEGF signaling complementing each other plays an important role in the progression of tumor angiogenesis in primary glioblastoma. PMID: 26472724
22. our data indicate that high DLL4 expression predicts pelvic lymph node metastasis and poor survival in cervical cancer. Therefore, DLL4 may be a potential clinical diagnostic marker for patients with early-stage cervical cancer. PMID: 26546434
23. Cyclic AMP Response Element Binding Protein Mediates Pathological Retinal Neovascularization via Modulating DLL4-NOTCH1 Signaling PMID: 26870802
24. DLL4 and JAG1 may have opposing effects on tumor angiogenesis in glioblastoma. PMID: 26546995
25. Expression of D114 in the vessels of dermal microvasculature was shown to increase from 20 weeks of gestation to 20 years. PMID: 27487663
26. Data indicate the role for altered forkhead box C2 (FoxC2)-Delta-like ligand 4 (Dll4)signaling in structural alterations of saphenous veins in patients with varicose veins. PMID: 26808710
27. Antagonism of the DLL4-Notch signaling pathway might provide a potential therapeutic approach for breast cancer treatment by preventing angiogenesis. PMID: 26739060
28. Activation of Dll4/Notch signaling led to increased expression of ephrin-B2 and subsequent inhibition of endothelial progenitor cells activity. PMID: 26212082
29. DLL4 is a unique functional molecule of human circulating dendritic cells critical for directing Th1 and Th17 differentiation PMID: 26712946
30. The expression of DLL4 was positively correlated with CD105-labeled MVD. PMID: 25986715
31. The detection of Notch1 and Delta-like 4 expression in peripheral blood lymphocytes of renal transplant recipients can serve as a positive indicator for evaluating the diagnosis and treatment efficacy of the AR reaction. PMID: 26070613
32. Among all the Notch ligands, Delta-like4 (Dll4) is specifically involved in angiogenesis. hD4R could suppress angiogenesis in vitro as manifested by network formation assay and sprouting assay. PMID: 25833803
33. DLL4 and VEGFA expression was closely related to tumour diameter, clinical stage, histological grade and lymph node metastasis. PMID: 26111775
34. DLL4/Notch1 and BMP9 interdependent signaling induces endothelial cell quiescence via P27KIP1/thrombospondin pathway. PMID: 26471266
35. Overexpression of DLL4 is associated with thyroid tumor invasion and metastasis. PMID: 26241546
36. Macrophage Dll4 promotes lesion development in vein grafts via macrophage activation and crosstalk between macrophages and smooth muscle cells. PMID: 26404485
37. Heterozygous Loss-of-Function Mutations in DLL4 Cause Adams-Oliver Syndrome. PMID: 26299364
38. IL-23 could promote migration of human ESCC cells by activating DLL4/Notch1 signaling pathway PMID: 26062426
39. expression of VEGF and Dll4/Notch pathway molecules in ovarian cancer PMID: 24949865
40. Dormant Dbf4 mRNA in immature GV oocytes is recruited by cytoplasmic polyadenylation during oocyte maturation and is dependent on MPF activity via its cytoplasmic polyadenylation element (CPE) PMID: 25348865
41. High DLL4 expression is associated with T acute lymphoblastic leukemia. PMID: 25355291
42. Inhibition of ADAM10/17 or knockdown of DLL4 reduced the proangiogenic effects of fibulin-3 in culture PMID: 25139440
43. Dll4 expression is up-regulated in clear cell renal cell carcinoma patients, and predicts poor prognosis. PMID: 24966922
44. Dengue virus up-regulates expression of notch ligands Dll1 and Dll4 through interferon-beta signalling pathway. PMID: 25041739
45. Our data suggest that renal cell carcinoma progression is caused in part by activated DLL4/Notch signaling, interaction of endothelium and cells PMID: 24931473
46. these results suggest that high expression of DLL4 is associated with axillary lymph node metastasis and a poor prognosis in breast cancer, suggesting its value as a diagnostic marker for breast cancer. PMID: 25260720
47. These findings indicate a potential role for the Notch-1-Dll4 signaling pathway in foreign body-induced granulomatous reactions PMID: 24394305
48. High expression of DLL4 is associated with metastasis in breast cancer. PMID: 24696220
49. findings suggest that ADAM10/Dll4 signaling is a major signaling pathway in ECs driving inflammatory events involved in inflammation and immune cell recruitment PMID: 25130545
50. Dll4-containing exosomes increase endothelial cell motility while suppressing their proliferation. PMID: 24504253
顯示更多

收起更多
相關疾病：

Adams-Oliver syndrome 6 (AOS6)
亞細胞定位：

Cell membrane; Single-pass type I membrane protein.
組織特異性：

Expressed in vascular endothelium.
數據庫鏈接：

HGNC: 2910

OMIM: 605185

KEGG: hsa:54567

STRING: 9606.ENSP00000249749

UniGene: Hs.511076